Results

Animals exposed to MCAO displayed the typical neurological deficit accompanied by cortical and subcortical infarction at 72 h post-stroke. The expression of MICU1, with co-localization with neurons, was detected at different time points (6 h and 12 h) after ischemic damage. Altogether, these observations revealed an up-regulation of MICU1 expression in the early stages of cerebral ischemia.

Conclusion

The results demonstrated that MICU1 was upregulated in neurons at the acute phase of ischemic stroke. Because MICU1 has been previously shown to participate in mitochondrial Ca2+ uptake mediated by MCU, our study further implicates the involvement of MICU1 in calcium overload-induced cell death which is closely associated with stroke.

Cerebral ischemia-induced injury is a complex pathophysiological process. Although the primary cause of ischemic stroke has been attributed to blood flow interruption, the specific mechanisms underlying the progression of the disease, in particular the secondary cell death processes remain not fully understood. A widely postulated cell death pathway implicated in stroke involves mitochondrial Ca2+ overload induced by mitochondrial Ca2+ uptake. Such aberrant mitochondrial Ca2+ overload has been shown to play a vital role in the onset and progression of pathophysiological process in the early phases of ischemia [1]. Previous studies have demonstrated that the mitochondrial calcium uniporter (MCU), which possesses two transmembrane domains and forms tetrameric highly specific mitochondrial Ca2+ channels, is responsible for the mitochondrial Ca2+ uptake [2]. Mitochondrial Ca2+ uptake 1 (MICU1) has been demonstrated to be a key regulator of MCU [3]. This MICU1 regulation (albeit inhibition) of MCU activation occurs at low cytosolic free Ca2+ concentration [Ca2+]c, while MICU1 as an activator of MCU ensues at high [Ca2+]c (2.5 μM) [3]. Interestingly, upregulated expression of MCU and increased [Ca2+]c accompany the early stages of cerebral ischemic damage [2, 3].

In view of the reported interaction between MICU1 and MCU, whereby MICU1 activates MCU at high [Ca2+]c [3], we advanced the hypothesis that if indeed MICU1 is involved in the early pathogenesis of stroke, then MICU1 upregulation should be detected acutely in discrete regions of the ischemic stroke brain. Thus, we examined here the expression of MICU1 both at protein and mRNA levels at the acute stages of experimentally induced ischemic stroke in animals. The results from this study should provide insights into the specific timing and brain regions associated with MICU1 upregulation after cerebral ischemia.

Animals and groups

We used adult male Sprague–Dawley rats which weighed between 250 and 280 g, purchased from Hebei Medical University Experimental Animal Center. All rats were kept on a 12 h-light/12 h-dark with humidity of 55 ± 5%, and had free access to food and water. Rats were randomly divided into eight groups as control (normal control), sham (sham operated), MCAO 3 h, MCAO 6 h, MCAO 12 h, MCAO 24 h, MCAO 48 h, MCAO 72 h. The brain samples were collected from the rats after decapitation. The sample size of n = 5 was estimated based power analysis taking into account our previous studies demonstrating the minimum number of samples needed to demonstrate 25% difference between treatment groups.

Permanent middle cerebral artery occlusion

Rats underwent permanent middle cerebral artery occlusion (MCAO) as previously described [4, 5]. After induction of anesthesia by intraperitoneal injection with 10% chloral hydrate (250 mg/kg), a nylon filament (diameter 0.265 mm) was inserted intraluminally into the Internal carotid artery (ICA) about 18 to 20 mm deep. Gentamicin was used to protect against infection at the incision site. Rats of the sham group received the same surgery except for the filament insertion. The body temperatures of the rats were maintained at 37 ± 1 °C by an electric blanket during the surgery. Moreover, physiological measures, including pH, pCO2, pO2, and systolic/diastolic blood pressure were recorded, and did not significantly differ among animals, confirming a homogenous set of stroke animals was enrolled in this study.

Neurological exam

All investigators testing the animals were blinded to the treatment condition. Animals were subjected to neurological exam by using a scale for grading the ischemic injury-induced dysfunctions as follows: 0, rats extend straight both forelimbs, indicating no observable deficit; 1, rats keep the left forelimb to the breast and extend straight the right forelimb; 2, rats show decreased resistance to lateral push in addition to behavior in score 1 without circling; 3, rats twist the upper half of their body in addition to behavior in score 2. The animal was subjected to this test 3 times, and the scores from all 3 tests were averaged to give a mean neurologic deficit score (maximum possible score, 9 points divided by 3 tests = 3).

Cerebral infarction assay

The volume of infarction was analyzed using the triphenyltetrazolium chloride (TTC), a histological assay for determining dehydrogenase activity. Under deep anesthesia (chloral hydrate, 500 mg/kg, i.p.) animals were perfused intracardiacally with saline. Brains were then harvested, blocked, and processed for TTC staining. The volume of infarction was measured in each slice and summed using computerized planimetry (PC-based Image Tools software). The volume of infarction was computed as: 2 mm (thickness of the slice) × [sum of the infarction area in all brain slices (mm2)]. To minimize artifacts produced by post-ischemic edema in the infarcted area, the infarction area in the ipsilateral hemisphere was indirectly measured by subtracting the non-infarcted area in the ipsilateral hemisphere from the total intact area of the contralateral hemisphere.

Western blot

The Total Protein Extraction Kit (Applygen Technologies Inc., Beijing, China) was used to obtain the total protein of the brain tissue, focusing on the peak area of ischemic tissue (bregma 1 to −1 mm). About 30 μg total protein samples were applied to electrophoresis and then transferred onto PVDF membranes (Millipore Corporation, USA) as previously described [6]. After being blocked with 5% milk for 1 h at room temperature, the membranes were incubated overnight at 4 °C with anti-MICU1 (1:500, Santa Cruz Biotechnology) diluted in 5% milk. Polyclonal mouse anti-beta actin antibody (1:3000, Bioworld Technology) was used as a loading control. Membranes were incubated by fluorescent labeling second antibodies (IRDye 800-conjugate rabbit anti-goat IgG or rabbit anti-mouse IgG 1:5000 dilution; Rockland, Gilbertsville, PA, USA) for 1 h at room temperature. We analyzed the relative density of bands on the Odyssey infrared scanner (LICOR Bioscience, Lincoln, NE, USA).

Immunohistochemical staining

Paraffin-embedded sections were used to evaluate the expression of MICU1 at 6 h and 12 h after MCAO as previously described [7]. The brains of the rats were fixed in 4% paraformaldehyde over 24 h at 4 °C, embedded in paraffin after being dehydrated in different gradients of alcohols. Then cut the brain into 5 μm per slice. Brain sections were blocked in 3% normal donkey serum and then incubated with MICU1 goat polyclonal antibody (1: 100, Santa Cruz Biotechnology) overnight at 4 °C. The secondary antibodies were used the next day (Zhongshan Biology Technology Company, Beijing, China). Five visual fields of the ischemic regions (bregma 1 to −1 mm which corresponded to core and peri-infarct areas to fully capture the extent of cell death) were selected to count the mean density value under a 400× microscope. A separate cohort of animals were also subjected to MCAO, with animals euthanized at 6 h and 12 h after stroke, and brains harvested as above, but processed for double-labeling of MICU1 (1: 100, Santa Cruz Biotechnology) and the neuronal marker MAP2 (1:100 Abcam). The regions of interest for estimation of MICU1 expression and MAP2 positive cells included the peak area of ischemic regions (bregma 1 to −1 mm), which were photographically captured (Axiophot2; Zeiss), and cells were quantified by counting per HPF view selected at random and corrected by the Abercrombie formula. Six captured fields in each coronal level, using three anterior-posterior levels, were used to analyze the MICU1 expression and MAP2 positive cells, using Scion Image software (Scion, Frederick, MD). Binary images were created using a distinct threshold, and then the positive areas were calculated.

Real-time quantitative polymerase chain reaction

Rats’ brain tissue, also focusing on the peak area of ischemic tissue (bregma 1 to −1 mm), was rapidly dissected and the total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA). RNA (2 μg) from each sample was applied to reverse transcribed for synthesized cDNA. Primers were synthesized by Shanghai Biological Engineering Technology Company Limited. Forward and reverse primers were 5’-TTCCTCACAACGGTGCTCTC-3’ and 5’-CCAGACTTGAGGGTGTTCCC-3’ for MICU1 and 5’-CCCATCTATGAGGGTTACGC-3’ and 5’-TTTAATGTCACGCACGATTTC-3’ for β-actin. Each sample was measured in triplicate and all samples were normalized by β-actin. Relative gene expression was calculated with the 2-ΔΔCT method and then analyzed using logarithmic transformation.

Data and statistical analysis

All results are shown as mean ± standard error. One-way ANOVA followed by Student-Newman-Keuls and LSD tests were applied for multiple comparisons. Mann–Whitney U test was applied for neurological deficit score. The differences with P < 0.05 were considered statistically significant.

We detected the expression of MICU1 at protein level by western blot with whole tissue lysates collected from the rats’ brain regions from bregma 1 to −1 mm. Our results suggested that the expression of MICU1 was not notably changed at 3 h after ischemia, while significantly increased at 6-12 h after the middle cerebral artery occlusion, then the expression decreased gradually (Fig. 2).

Fig. 2

Western blot analysis of MICU1 at different time points after cerebral ischemia. MICU1 was significantly increased at 6-12 h after the MCAO, then the expression decreased gradually (n = 5, *p < 0.05, one way ANOVA)

We further measured the expression of MICU1 by immunohistochemistry in the neurons located in the same region of ischemic brains subject to MCAO at 6 and 12 h after ischemia. As expected, obviously increased MICU1 were found at both 6 h and12h (Fig. 3), which was consistent with the results of Western blot. These results suggested that the expression of MICU1 was indeed up-regulated at protein level after ischemia.

Fig. 3

Immunohistochemical staining of MICU1 at 6 h and 12 h after cerebral ischemia. Compared with control and sham groups, the mean density of MICU1 expression was significantly increased in both 6 h and 12 h after MCAO (n = 5, *p < 0.05, one way ANOVA). Co-labeling of MICU1 and the neuronal marker MAP2 revealed about 80% co-localization of phenotypic expression, as shown in MICU1/MAP2 ratio, in both 6 h and 12 h after MCAO. Scale bar = 100 μm

Expression of MICU1 is significantly increased at mRNA level after cerebral ischemia

In this study, we also measured the mRNA level of MICU1 at brain regions from bregma 1 to −1 mm after cerebral ischemia. Real-time quantitative PCR (qPCR) was used to detect the change of MICU1 mRNA expression at different time points after MCAO in rats as previously described [8]. We obtained consistent results in Western blot assays, showing that mRNA expression of MICU1 increased at 6-12 h after brain ischemia, and gradually decreased after 12 h (Fig. 4).

Fig. 4

Real-time quantitative PCR analysis of MICU1 at different time points after cerebral ischemia. Compared with normal control group and other time points, mRNA expression of MICU1 was increased at 6-12 h after MCAO (n = 5, *p < 0.05, one way ANOVA)

The present study revealed that MICU1 expression was upregulated in the early stage (6 h and 12 h) of cerebral ischemia. The expression of MICU1 was co-localization with neurons in ischemic regions of the brain, suggesting an intimate association of MICU1 expression and the evolving pathology in acute stroke.

Ca2+ overload plays an important role in pathophysiological process after cerebral ischemic damage [1]. Previous studies showed that a rise of calcium concentration signals an increased cellular energy demand and mediates a number of pathways that can precipitate mitochondrial injury and cell death [9]. Of interest, increments in [Ca2+]c are detected at the acute phases after MCAO [10–12]. At approximately the same time, the expression of MCU is up-regulated [13]. Of interest, the aberrant pathophysiological cascade of cell death events at the early stage of cerebral ischemia may involve MCU-mediated Ca2+ alterations that can lead to perturbed homeostasis [1, 9, 13]. That MICU1 is a key regulator of MCU implicates MICU1 serving a pivotal role in the initial progression of stroke. In particular, MICU1 can activate MCU at high [Ca2+]c [3], which can subsequently promote MCU-induced mitochondrial Ca2+ uptake and ultimately cell death. However, this remains speculative as we have not yet established that the upregulation of MICU1 expression directly modulates MCAO onset and progression.

Additional studies are warranted to demonstrate cause-and-effect relationship between MICU1 and MCAO, which may include the use gene and pharmacologic knockout or inhibition of MICU1. At best, our study showed that the expression of MICU1 was up-regulated in acute ischemic stroke, which paralleled previous studies demonstrating elevated [Ca2+]c and increased MCU at the same time period.

Our results indicate that MICU1 upregulation accompanied acute ischemic stroke. Because MICU1 is involved in Ca2+ homeostasis by regulating MCU activation, this study supports MICU1 as a novel molecular target for abrogating the calcium overload detected in the early phase of cerebral ischemia.

Acknowledgement

The authors acknowledge the funding sources listed above. The authors thank Dr. Cesario V Borlongan, of Department of Neurosurgery and Brain Repair and Center of Excellence for Aging and Brain Repair in University of South Florida College of Medicine, for his help and enlightening discussions with paper submission and revising.

Funding

This research was supported primarily by NSFC grants to Xiaoyun Liu from the National Natural Science Foundation of China (81571160); Second Hospital of Hebei Medical University Research Fund (2 h2201506); Key project of medical research in Hebei Province (20150668), and in part by Washington Institute for Health Sciences fund.

Availability of data and materials

The datasets supporting the conclusions of this article are available at the investigators’ research centers located at the Second Hospital of Hebei Medical University.

Authors’ contributions

The authors contributed equally to the conceptualization and write-up of this manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The use of animals in this study received approval from the Second Hospital of Hebei Medical University (Research Ethics Committee of the Second Hospital of Hebei Medical University, Permit Number: 2016131).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.